BR1018
/ Boryung Group
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 13, 2025
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=60 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Not yet recruiting ➔ Completed
Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
March 21, 2025
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd
New P1 trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
May 24, 2023
A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=36 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Recruiting ➔ Completed | Trial completion date: Apr 2023 ➔ Oct 2022 | Trial primary completion date: Jan 2023 ➔ Oct 2022
Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
July 15, 2022
A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd
New P1 trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
1 to 4
Of
4
Go to page
1